CAN-296-P is effective against cutaneous candidiasis in guinea pigs

Avital M. Ben-Josef, Jessica L. Cutright, Elias K. Manavathu, Jack D. Sobel

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

CAN-296 is a naturally occurring, heat-stable complex carbohydrate isolated from the cell wall of Mucor rouxii. Previously, CAN-296 demonstrated impressive in vitro fungicidal activity against a wide spectrum of pathogenic yeast, including azole-resistant isolates. The effect of CAN-296 on Candida albicans is rapid, concentration-dependent, and lethal. CAN-296-P is a chitosan-pyrithione derivative of CAN-296 containing 4% solution of chitosan with 25% substitution of pyrithione. Like CAN-296, it has in vitro fungicidal activity with a minimum inhibitory concentration (MIC) of 0.156 mg/l for C. albicans. The therapeutic effect of topical CAN-296-P on cutaneous candidiasis caused by C. albicans in guinea pigs was investigated. Three different C. albicans isolates, including one fluconazole-resistant strain (R 637601-9), were tested. After immunosuppression with cyclophosphamide, infection under occlusive dressing was achieved and treated within 48 h after the initial infection. Once-a-day topical application of 0.125, 0.25, 0.5, 1, 2, and 4% CAN-296-P solution was administrated for a period of 1, 3, 5, and 7 days. CAN-296-P at a concentration ≥0.25% was found to be as effective in clearing the infection as was 2% miconazole. Effectiveness in eradicating candidiasis with CAN-296-P was concentration-dependent and free of local adverse effects. Can-296-P is a novel, highly active topical fungicidal agent, with broad potential for clinical use.

Original languageEnglish (US)
Pages (from-to)168-171
Number of pages4
JournalInternational Journal of Antimicrobial Agents
Volume22
Issue number2
DOIs
StatePublished - Aug 1 2003

Fingerprint

Cutaneous Candidiasis
Guinea Pigs
Candida albicans
Chitosan
Infection
Occlusive Dressings
CAN 296
Miconazole
Mucor
Azoles
Fluconazole
Candidiasis
Microbial Sensitivity Tests
Therapeutic Uses
Cyclophosphamide
Immunosuppression
Cell Wall

Keywords

  • Antifungal agent
  • Candida albicans
  • Complex carbohydrate
  • In vivo fungal infection

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)

Cite this

CAN-296-P is effective against cutaneous candidiasis in guinea pigs. / Ben-Josef, Avital M.; Cutright, Jessica L.; Manavathu, Elias K.; Sobel, Jack D.

In: International Journal of Antimicrobial Agents, Vol. 22, No. 2, 01.08.2003, p. 168-171.

Research output: Contribution to journalArticle

Ben-Josef, Avital M. ; Cutright, Jessica L. ; Manavathu, Elias K. ; Sobel, Jack D. / CAN-296-P is effective against cutaneous candidiasis in guinea pigs. In: International Journal of Antimicrobial Agents. 2003 ; Vol. 22, No. 2. pp. 168-171.
@article{c09f78967af4405bacba15b09a176055,
title = "CAN-296-P is effective against cutaneous candidiasis in guinea pigs",
abstract = "CAN-296 is a naturally occurring, heat-stable complex carbohydrate isolated from the cell wall of Mucor rouxii. Previously, CAN-296 demonstrated impressive in vitro fungicidal activity against a wide spectrum of pathogenic yeast, including azole-resistant isolates. The effect of CAN-296 on Candida albicans is rapid, concentration-dependent, and lethal. CAN-296-P is a chitosan-pyrithione derivative of CAN-296 containing 4{\%} solution of chitosan with 25{\%} substitution of pyrithione. Like CAN-296, it has in vitro fungicidal activity with a minimum inhibitory concentration (MIC) of 0.156 mg/l for C. albicans. The therapeutic effect of topical CAN-296-P on cutaneous candidiasis caused by C. albicans in guinea pigs was investigated. Three different C. albicans isolates, including one fluconazole-resistant strain (R 637601-9), were tested. After immunosuppression with cyclophosphamide, infection under occlusive dressing was achieved and treated within 48 h after the initial infection. Once-a-day topical application of 0.125, 0.25, 0.5, 1, 2, and 4{\%} CAN-296-P solution was administrated for a period of 1, 3, 5, and 7 days. CAN-296-P at a concentration ≥0.25{\%} was found to be as effective in clearing the infection as was 2{\%} miconazole. Effectiveness in eradicating candidiasis with CAN-296-P was concentration-dependent and free of local adverse effects. Can-296-P is a novel, highly active topical fungicidal agent, with broad potential for clinical use.",
keywords = "Antifungal agent, Candida albicans, Complex carbohydrate, In vivo fungal infection",
author = "Ben-Josef, {Avital M.} and Cutright, {Jessica L.} and Manavathu, {Elias K.} and Sobel, {Jack D.}",
year = "2003",
month = "8",
day = "1",
doi = "10.1016/S0924-8579(03)00111-0",
language = "English (US)",
volume = "22",
pages = "168--171",
journal = "International Journal of Antimicrobial Agents",
issn = "0924-8579",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - CAN-296-P is effective against cutaneous candidiasis in guinea pigs

AU - Ben-Josef, Avital M.

AU - Cutright, Jessica L.

AU - Manavathu, Elias K.

AU - Sobel, Jack D.

PY - 2003/8/1

Y1 - 2003/8/1

N2 - CAN-296 is a naturally occurring, heat-stable complex carbohydrate isolated from the cell wall of Mucor rouxii. Previously, CAN-296 demonstrated impressive in vitro fungicidal activity against a wide spectrum of pathogenic yeast, including azole-resistant isolates. The effect of CAN-296 on Candida albicans is rapid, concentration-dependent, and lethal. CAN-296-P is a chitosan-pyrithione derivative of CAN-296 containing 4% solution of chitosan with 25% substitution of pyrithione. Like CAN-296, it has in vitro fungicidal activity with a minimum inhibitory concentration (MIC) of 0.156 mg/l for C. albicans. The therapeutic effect of topical CAN-296-P on cutaneous candidiasis caused by C. albicans in guinea pigs was investigated. Three different C. albicans isolates, including one fluconazole-resistant strain (R 637601-9), were tested. After immunosuppression with cyclophosphamide, infection under occlusive dressing was achieved and treated within 48 h after the initial infection. Once-a-day topical application of 0.125, 0.25, 0.5, 1, 2, and 4% CAN-296-P solution was administrated for a period of 1, 3, 5, and 7 days. CAN-296-P at a concentration ≥0.25% was found to be as effective in clearing the infection as was 2% miconazole. Effectiveness in eradicating candidiasis with CAN-296-P was concentration-dependent and free of local adverse effects. Can-296-P is a novel, highly active topical fungicidal agent, with broad potential for clinical use.

AB - CAN-296 is a naturally occurring, heat-stable complex carbohydrate isolated from the cell wall of Mucor rouxii. Previously, CAN-296 demonstrated impressive in vitro fungicidal activity against a wide spectrum of pathogenic yeast, including azole-resistant isolates. The effect of CAN-296 on Candida albicans is rapid, concentration-dependent, and lethal. CAN-296-P is a chitosan-pyrithione derivative of CAN-296 containing 4% solution of chitosan with 25% substitution of pyrithione. Like CAN-296, it has in vitro fungicidal activity with a minimum inhibitory concentration (MIC) of 0.156 mg/l for C. albicans. The therapeutic effect of topical CAN-296-P on cutaneous candidiasis caused by C. albicans in guinea pigs was investigated. Three different C. albicans isolates, including one fluconazole-resistant strain (R 637601-9), were tested. After immunosuppression with cyclophosphamide, infection under occlusive dressing was achieved and treated within 48 h after the initial infection. Once-a-day topical application of 0.125, 0.25, 0.5, 1, 2, and 4% CAN-296-P solution was administrated for a period of 1, 3, 5, and 7 days. CAN-296-P at a concentration ≥0.25% was found to be as effective in clearing the infection as was 2% miconazole. Effectiveness in eradicating candidiasis with CAN-296-P was concentration-dependent and free of local adverse effects. Can-296-P is a novel, highly active topical fungicidal agent, with broad potential for clinical use.

KW - Antifungal agent

KW - Candida albicans

KW - Complex carbohydrate

KW - In vivo fungal infection

UR - http://www.scopus.com/inward/record.url?scp=0043091883&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0043091883&partnerID=8YFLogxK

U2 - 10.1016/S0924-8579(03)00111-0

DO - 10.1016/S0924-8579(03)00111-0

M3 - Article

C2 - 12927959

AN - SCOPUS:0043091883

VL - 22

SP - 168

EP - 171

JO - International Journal of Antimicrobial Agents

JF - International Journal of Antimicrobial Agents

SN - 0924-8579

IS - 2

ER -